Contrasting Guardant Health (GH) & The Competition

Share on StockTwits

Guardant Health (NASDAQ: GH) is one of 24 publicly-traded companies in the “Medical laboratories” industry, but how does it compare to its competitors? We will compare Guardant Health to related businesses based on the strength of its risk, dividends, institutional ownership, valuation, earnings, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Guardant Health and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Guardant Health 0 1 4 0 2.80
Guardant Health Competitors 173 627 736 46 2.41

Guardant Health presently has a consensus price target of $72.50, suggesting a potential downside of 5.70%. As a group, “Medical laboratories” companies have a potential upside of 14.41%. Given Guardant Health’s competitors higher probable upside, analysts plainly believe Guardant Health has less favorable growth aspects than its competitors.

Profitability

This table compares Guardant Health and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Guardant Health N/A N/A N/A
Guardant Health Competitors -105.92% -115.51% -34.04%

Insider and Institutional Ownership

69.6% of Guardant Health shares are owned by institutional investors. Comparatively, 52.0% of shares of all “Medical laboratories” companies are owned by institutional investors. 17.1% of shares of all “Medical laboratories” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Guardant Health and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Guardant Health $90.64 million -$85.06 million -27.46
Guardant Health Competitors $1.13 billion $64.24 million -1.79

Guardant Health’s competitors have higher revenue and earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Guardant Health Company Profile

Guardant Health, Inc., a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA. The company also provides LUNAR-1 for recurrence detection in cancer survivors; and LUNAR-2 for early detection of cancer in higher risk individuals. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Enable Midstream Partners  versus Transportadora de Gas del Sur  Head to Head Analysis
Enable Midstream Partners versus Transportadora de Gas del Sur Head to Head Analysis
Analyzing IMAC  & BioTelemetry
Analyzing IMAC & BioTelemetry
Pledge Petroleum  vs. Westlake Chemical Partners  Head-To-Head Analysis
Pledge Petroleum vs. Westlake Chemical Partners Head-To-Head Analysis
Analyzing Westwood Holdings Group  & Legg Mason
Analyzing Westwood Holdings Group & Legg Mason
Short Interest in Income Opportunity Realty Investors Inc  Declines By 50.0%
Short Interest in Income Opportunity Realty Investors Inc Declines By 50.0%
Nuverra Environmental Solutions Inc  Sees Significant Growth in Short Interest
Nuverra Environmental Solutions Inc Sees Significant Growth in Short Interest


© 2006-2019 Ticker Report